Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Multiple Myeloma 74Lymphoma, Follicular 20Lymphoma, Large B-Cell, Diffuse 19Neoplasms, Plasma Cell 11Lymphoma, Mantle-Cell 8Lymphoma, B-Cell, Marginal Zone 8Recurrence 7Smoldering Multiple Myeloma 6Lymphoma, B-Cell 6Leukemia, Lymphocytic, Chronic, B-Cell 6Neoplasms 5Lymphoma 5Lymphoma, Non-Hodgkin 4Burkitt Lymphoma 3Plasmacytoma 2Neuroblastoma 2Neoplasm, Residual 2Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Neurologic Manifestations 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Primary Effusion 1Lymphoma, AIDS-Related 1Leukemia, Plasma Cell 1Leukemia 1Histiocytosis, Langerhans-Cell 1

Interventions

Vorinostat 1Lenalidomide 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × GATA2 Deficiency × Lenalidomide × Clear all
NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡